The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 6% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (5 analysts) rates it buy, with a mean price target of $54. Since the last review it its quality tier rose to Gold; its composite score rose.
Rigel Pharmaceuticals
RIGL · NASDAQ · USD · Market cap $734M · 172 employees
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
PASS · Titan Ethical · score 70.0Price as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price44.46 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.35)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $68.75 to $88.92, base estimate $68.75 (screen dated 2026-11-13).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.35, read 2026-11-15
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Rigel Pharmaceuticals holds its Distribution at $44.46. The statistical read favours the buyers, held for 2 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the buyers, held for 2 days |
| Price at the screen | $44.46 |
| Valuation | 2.35 trailing · 8.03 forward price to earnings |
| Values screen | PASS · score 70.0 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 10.38% | Below 33% | Interest-bearing debt is just 10.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 22.27% | Below 33% | Cash held in interest-bearing accounts and securities is 22.3% of assets, under the one-third limit. | Pass |
| Receivables | 17.98% | Below 49% | Money owed to the company is 18.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.25% | Below 5% | Only 1.3% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Rigel Pharmaceuticals clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 10%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RIGL's ethical verdict changes
Today RIGL passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 35% discount to our $68.75 fair value, none competitive moat, 16.50% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 35.3% discount to the base estimate.
Third-party analyst targets: 5 covering, consensus Buy. The average target sits +24% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $68.75, with a range of $68.75 to $88.92, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it stands out
A 17%-growth business trading at just 8.0x forward earnings, with a none competitive moat. That is a 35% discount to our $68.75 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 5 analysts rate it Buy with a $55.00 average target, about 24% above the screened price.
| Forward P/E | 8.0xcheap for a company growing this fast |
| Trailing P/E | 2.3xvery cheap relative to earnings |
| EPS, trailing | 16.88 |
| EPS, forward | 4.94 |
| Revenue growth | +16.5%steady growth |
| Profit margin | 106.6%highly profitable on every dollar of sales |
| Return on equity | 109.2%an exceptional return on shareholder capital |
| FCF yield | -1.88% |
| Debt to equity | 1.75a meaningful debt load worth watching |
| Current ratio | 2.39comfortably covers its short-term bills |
| Short interest, float | 0.15% |
| 52-week range | 24.95 - 52.61 |
| Moat | NONE |
| Market cap | $734M |
| Employees | 172 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeRIGL trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (5 analysts) rates it buy, with a mean price target of $54. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (5 analysts) rates it buy, with a mean price target of $54. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (5 analysts) rates it buy, with a mean price target of $54. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (5 analysts) rates it buy, with a mean price target of $54. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (5 analysts) rates it buy, with a mean price target of $54. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (5 analysts) rates it buy, with a mean price target of $54. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (5 analysts) rates it buy, with a mean price target of $54. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (5 analysts) rates it buy, with a mean price target of $54. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (5 analysts) rates it buy, with a mean price target of $54. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Rigel to Present at the Jefferies Global Healthcare Conference in London Yahoo Finance · 6d ago
- Rigel Pharmaceuticals Q3 Earnings Call Highlights Yahoo Finance · 9d ago
- Rigel Pharmaceuticals Inc (RIGL) (Q3 2026) Earnings Call Highlights: Record Product Sales of ... Yahoo Finance · 9d ago
- Rigel Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary Yahoo Finance · 10d ago
- Rigel (RIGL) Q3 2026 Earnings Call Transcript Yahoo Finance · 10d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $26.20 | +18.1% | · | $1,181 | +18.1% |
| 2 months | $29.20 | +5.9% | · | $1,059 | +5.9% |
| 3 months | $26.60 | +16.3% | · | $1,163 | +16.3% |
| 6 months | $42.05 | -26.4% | · | $736 | -26.4% |
| 1 year | $21.56 | +43.5% | · | $1,435 | +43.5% |
| 2 years | $10.20 | +203.2% | · | $3,032 | +203.2% |
| 3 years | $16.10 | +92.1% | · | $1,921 | +92.1% |
| 5 years | $40.20 | -23.1% | · | $769 | -23.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever RIGL does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.